OCUP Ocuphire Pharma Inc

Opus Genetics to Participate in the H.C. Wainwright 27th Annual Global Investment Conference

Opus Genetics to Participate in the H.C. Wainwright 27th Annual Global Investment Conference

RESEARCH TRIANGLE PARK, N.C., Sept. 03, 2025 (GLOBE NEWSWIRE) -- (Nasdaq: IRD) (the “Company” or “Opus Genetics”), a clinical-stage biopharmaceutical company developing gene therapies for the treatment of inherited retinal diseases (IRDs) and small molecule therapies for other ophthalmic disorders, announced today that George Magrath, MD, Chief Executive Officer, and Ash Jayagopal, Ph.D., MBA, Chief Scientific and Development Officer, will deliver a corporate update at the H.C. Wainwright 27th Annual Global Investment Conference being held September 8-10, 2025. The presentation will be available on demand on Monday, September 8, 2025 at 7:00 a.m. ET.

In addition, replays from other recent investor events are available on the Opus Genetics’ website, including:

  • Nasdaq Spotlight interview
  • Chardan Virtual Ophthalmology Summit Series on Rare Ophthalmic Diseases Fireside Chat
  • Jones Trading Virtual Presbyopia Expert Panel

Links to these webcasts may be accessed on the Opus Genetics website under the Investors section: .

About Opus Genetics

Opus Genetics is a clinical-stage biopharmaceutical company developing gene therapies for the treatment of inherited retinal diseases (IRDs) and small molecule therapies for other ophthalmic disorders. The Company’s pipeline features AAV-based gene therapies targeting inherited retinal diseases including Leber congenital amaurosis (LCA), bestrophinopathy, and retinitis pigmentosa. Its lead gene therapy candidates are OPGx-LCA5, which is in an ongoing Phase 1/2 trial for LCA5-related mutations, and OPGx-BEST1, a gene therapy targeting BEST1-related retinal degeneration. Opus Genetics is also advancing Phentolamine Ophthalmic Solution 0.75%, a partnered therapy currently approved in one indication and being studied in two Phase 3 programs for presbyopia and reduced low light vision and nighttime visual disturbances. The Company is based in Research Triangle Park, NC. For more information, visit .

Contacts:

Investors

Jenny Kobin

Remy Bernarda

IR Advisory Solutions

Media

Kimberly Ha

KKH Advisors

917-291-5744

Source: Opus Genetics, Inc.



EN
03/09/2025

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Ocuphire Pharma Inc

 PRESS RELEASE

Opus Genetics Reports Positive Pediatric Data from OPGx-LCA5 Phase 1/2...

Opus Genetics Reports Positive Pediatric Data from OPGx-LCA5 Phase 1/2 Trial in Leber Congenital Amaurosis Type 5 (LCA5) Pediatric participants demonstrated large gains in cone-mediated vision; therapy remains well tolerated with no ocular serious adverse events or dose-limiting toxicitiesLasting, durable responses observed out to 18 months in adult participantsExpected FDA Meeting in Q4 2025Management to Host Webcast and Conference Call Today at 8:30 A.M. ET RESEARCH TRIANGLE PARK, N.C., Sept. 30, 2025 (GLOBE NEWSWIRE) -- . (Nasdaq: IRD), a clinical-stage biopharmaceutical company dev...

 PRESS RELEASE

Opus Genetics Reports Inducement Grant Under Nasdaq Listing Rule 5635(...

Opus Genetics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) RESEARCH TRIANGLE PARK, N.C., Sept. 12, 2025 (GLOBE NEWSWIRE) -- Opus Genetics, Inc. (Nasdaq: IRD), a clinical-stage biopharmaceutical company developing gene therapies for the treatment of inherited retinal diseases (IRDs) and small molecule therapies for other ophthalmic disorders (the “Company”), today announced that the Compensation Committee of its Board of Directors approved equity awards under the Company’s 2021 Inducement Plan, as amended, as a material inducement to employment to Rob Gagnon the Company’s ...

 PRESS RELEASE

Opus Genetics Doses First Patient in Pivotal LYNX-3 Phase 3 Trial Eval...

Opus Genetics Doses First Patient in Pivotal LYNX-3 Phase 3 Trial Evaluating Phentolamine Ophthalmic Solution 0.75% in Keratorefractive Patients With Visual Disturbances Under Mesopic, Low-Contrast Conditions RESEARCH TRIANGLE PARK, N.C., Sept. 04, 2025 (GLOBE NEWSWIRE) -- . (Nasdaq: IRD), a clinical-stage biopharmaceutical company developing gene therapies for inherited retinal diseases (IRDs) and small-molecule therapies for other ophthalmic disorders, today announced that the first patient has been dosed in LYNX-3, the Company’s pivotal Phase 3 clinical trial evaluating Phentolamine Op...

 PRESS RELEASE

Opus Genetics to Participate in the H.C. Wainwright 27th Annual Global...

Opus Genetics to Participate in the H.C. Wainwright 27th Annual Global Investment Conference RESEARCH TRIANGLE PARK, N.C., Sept. 03, 2025 (GLOBE NEWSWIRE) -- (Nasdaq: IRD) (the “Company” or “Opus Genetics”), a clinical-stage biopharmaceutical company developing gene therapies for the treatment of inherited retinal diseases (IRDs) and small molecule therapies for other ophthalmic disorders, announced today that George Magrath, MD, Chief Executive Officer, and Ash Jayagopal, Ph.D., MBA, Chief Scientific and Development Officer, will deliver a corporate update at the H.C. Wainwright 27th An...

 PRESS RELEASE

Opus Genetics Appoints Rob Gagnon as Chief Financial Officer

Opus Genetics Appoints Rob Gagnon as Chief Financial Officer RESEARCH TRIANGLE PARK, N.C., Sept. 02, 2025 (GLOBE NEWSWIRE) -- . (Nasdaq: IRD), a clinical-stage biopharmaceutical company developing gene therapies for inherited retinal diseases (IRDs) and small molecule therapies for other ophthalmic disorders, today announced the appointment of Rob Gagnon, CPA, MBA, as Chief Financial Officer. Mr. Gagnon is an accomplished biotech executive with more than two decades of financial and operational leadership experience in both public and private companies. He has raised over $2 billion in c...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch